Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The impact of programmed death ligand 1 expression on prognosis in penile cancer: a systematic review and meta-analysis.

Created on 03 Nov 2026

Authors

Diarmuid D Sugrue, Orla Cullivan, Eoghan Cunnane, Niall Davis, Min Yuen Teo, Ivor Cullen

Published in

BJU international. Nov 03, 2026. Epub Nov 03, 2026.

Abstract

To determine the prevalence of programmed death ligand 1 (PD-L1) expression in penile squamous cell carcinoma (PSCC) and evaluate its associations with clinicopathological features and survival outcomes.
A systematic review was carried out using PubMed, the Excerpta Medica dataBASE (EMBASE), Scopus, Web of Science and Cochrane. Random-effects meta-analysis synthesised prevalence, hazard ratios (HRs) for overall survival (OS) and cancer-specific survival (CSS), and odds ratios (ORs) for lymph node metastases (LNM) and tumour characteristics. Meta-regression was caried out for pre-specified moderators.
A total of 16 studies (1634 patients) were included, with median follow-up of 44 months. The pooled PD-L1 prevalence was 53% (95% confidence interval [CI] 44-62%) with substantial between-study heterogeneity. PD-L1 positivity was associated with worse CSS (HR 1.94, 95% CI 1.54-2.44; P < 0.001) but not OS (HR 1.28, 95% CI 0.89-1.86; P = 0.2). PD-L1 positivity was associated with higher tumour stage (pathological T stage [pT]1 vs pT2-4, OR 1.67, 95% CI 1.22-2.29, P = 0.001), higher tumour grade (Grade 1 vs Grade 2-3, OR 2.60, 95% CI 1.94-3.5, P < 0.001), and LNM (OR 2.32, 95% CI 1.57-3.42, P < 0.001). Sensitivity testing and meta-regression did not materially alter pooled effects.
Programmed death ligand 1 is associated with adverse clinicopathological features and worse CSS in PSCC. Prospective validation is required to assess its independent prognostic value. Similarly PD-L1's predictive value for immunotherapy benefit cannot be determined from the current evidence and requires evaluation with treatment-specific prospective studies.

PMID:
42974892
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement